Ciprofloxacin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Ciprofloxacin: Diffuse scleroderma
One-Sentence Summary
Ciprofloxacin is a fluoroquinolone antibiotic, originally used for bacterial infections such as typhoid fever, salmonellosis, bacterial pneumonia, anthrax and Pseudomonas aeruginosa infections. The TxGNN model predicts it may be effective for diffuse scleroderma, but there are no registered clinical trials and only 2 publications, both indirect or of unverified design, so this prediction rests mostly on computation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Diffuse scleroderma |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ciprofloxacin is a fluoroquinolone antibacterial. Its efficacy in bacterial infections is well established, and it may be applicable to diffuse scleroderma through two indirect routes, neither of which is established.
- Possible antifibrotic effect in skin. One publication (PMID 20507401) examined oral ciprofloxacin as an antifibrotic in the skin of scleroderma patients. Scleroderma is an autoimmune connective tissue disorder marked by microvascular injury, excessive skin fibrosis and internal organ involvement, and no effective pharmacological treatment for the fibrosis exists. The antifibrotic effect has not been confirmed clinically.
- Treatment of a complication. Small bowel bacterial overgrowth is common in systemic sclerosis (PMID 7728404), so an antibiotic may help gastrointestinal symptoms such as chronic diarrhoea and weight loss. This addresses a complication rather than the underlying disease.
Both links are indirect, and the data compiled for this report contain no registered trials.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20507401 | 2010 | Exploratory study (design not verified; the abstract describes a controlled, double-blind randomized trial of oral ciprofloxacin) | The Journal of Dermatology | Assessed whether oral ciprofloxacin reduces scleroderma severity, with skin fibrosis as the focus. Results are not visible in the available abstract text. |
| 7728404 | 1995 | Cohort / diagnostic study | British Journal of Rheumatology | In 24 systemic sclerosis patients with malabsorption symptoms, small bowel bacterial overgrowth was assessed by direct and indirect methods, and treatment outcome was reported. It supports antibiotic use for a gastrointestinal complication, not for the disease itself. |
India Market Information
Ciprofloxacin has 20 valid single-ingredient registrations in India and none are cancelled. Dosage forms are oral tablets (strips of 10 or 15) and an intravenous infusion (100 ml bottle). Approved-indication text was not recorded for these licences. Five main authorizations:
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| 78463 | Euflox 500mg Tablet | Strip of 15 tablets |
| 3838 | Acebid SP Tablet | Strip of 10 tablets |
| 46934 | Cipti 250mg/300mg Tablet | Strip of 10 tablets |
| 52255 | CIPDOSE 200MG INFUSION | Bottle of 100 ml infusion |
| 85551 | Floxip OZ 500mg/500mg Tablet (Abbott) | Strip of 10 tablets |
Safety Considerations
- Disease-level cautions (from a knowledge graph, not label text): long QT syndrome, torsades de pointes, epilepsy, kidney disease, potassium deficiency, tendinitis and other tendon disorders (e.g., Achilles bursitis, heel spur), peripheral neuropathy, myasthenia gravis, Clostridium difficile colitis, and necrotizing enterocolitis. Tendon, nerve and gastrointestinal cautions deserve attention in scleroderma, a disease that already involves the gut and peripheral tissues.
- Drug Interactions: 417 interactions were identified. Those rated Major include hydrocortisone, triamcinolone, dexamethasone, betamethasone and bupropion. Moderate interactions include metformin, pioglitazone, alogliptin, albiglutide, acarbose, famotidine, loperamide, aspirin and budesonide. The corticosteroid interactions need particular care if the drug were used in a population that may also receive steroids.
For other safety information, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score (0.9987) is not backed by registered trials or confirmed clinical results. The two available publications are indirect, with one of unverified design, and the mechanistic links address either an unproven antifibrotic effect or a complication of the disease.
To proceed, the following is needed:
- The full results and methodological verification of the 2010 ciprofloxacin scleroderma study (PMID 20507401)
- Detailed mechanism of action data, to support an antifibrotic hypothesis
- Package insert warnings and contraindications from the Indian licences
- A safety assessment for scleroderma patients, covering tendon, neuropathy, QT and steroid-interaction risks
- A prospective controlled trial if the antifibrotic signal is confirmed
It is better seen as an extension of ciprofloxacin’s existing antibacterial use than as true repurposing, and its evidence for the septicemic form is indirect.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.